A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Trial Profile

A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Hyaluronidase (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HALO-202
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 12 Oct 2017 According to the results presented at the 42nd European Society for Medical Oncology Congress, due to an imbalance in thromboembolic (TE) events in the PAG arm, the protocol was amended to add enoxaparin and exclude pts at high risk for TE events in Stage 2.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results assessing the Musculoskeletal events with Pegylated recombinant human hyaluronidase treatment, presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top